{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T11:14:49Z","timestamp":1793272489669,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Pegvisomant (PEG) efficaciously controls IGF-I excess in acromegaly and possesses a positive impact on glucose metabolism. Data on very prolonged PEG treatment are still limited, therefore, we investigated the effects of 10-years PEG on disease control, maximal tumour diameter (MTD), and metabolic profile in consecutive patients resistant to somatostatin analogues (SRLs) followed in an European referral centre for acromegaly.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Since the 2000s, we collected data on anthropometric, hormonal and metabolic parameters, and MTD of patients receiving PEG. In the current study, we included 45 patients (19 men, 26 women, 46.8\u2009\u00b1\u200911\u00a0years) treated for at least 5\u00a0years with PEG mono or combined therapy, analyzing data before, after 5- and 10-years PEG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>After10 years, 91% of\u00a0patients showed full\u00a0disease control and in 37% a significant decrease in MTD was found. Diabetes prevalence was slightly\u00a0increased, whereas HbA1c remained stable over the decade. Transaminases remained stable and no case of cutaneous lipohypertrophy was recorded. A different metabolic impact between mono- or combined therapy was found. Patients in monotherapy showed significantly lower fasting glucose (<jats:italic>p<\/jats:italic>\u2009=\u20090.01), fasting insulin (<jats:italic>p<\/jats:italic>\u2009=\u20090.008), HbA1c (<jats:italic>p<\/jats:italic>\u2009=\u20090.007), HOMA-IR (<jats:italic>p<\/jats:italic>\u2009=\u20090.001), and significantly higher ISI<jats:sub>0<\/jats:sub> (<jats:italic>p<\/jats:italic>\u2009=\u20090.002), whereas patients under combined therapy showed significantly lower total (<jats:italic>p<\/jats:italic>\u2009=\u20090.03), and LDL cholesterol (<jats:italic>p<\/jats:italic>\u2009=\u20090.007). Acromegaly duration before PEG was inversely related to \u0394FG (<jats:italic>r<\/jats:italic>\u2009=\u2009\u2212\u00a00.46, <jats:italic>p<\/jats:italic>\u2009=\u20090.03) and \u0394FI (<jats:italic>r<\/jats:italic>\u2009=\u2009\u2212\u00a00.54, <jats:italic>p<\/jats:italic>\u2009=\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>PEG is effective and safe in long term. In patients resistant to SRLs, early beginning of PEG\u00a0allows a wider gluco-insulinemic improvement.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s40618-022-01980-7","type":"journal-article","created":{"date-parts":[[2023,3,26]],"date-time":"2023-03-26T20:50:58Z","timestamp":1679863858000},"page":"1027-1038","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience"],"prefix":"10.1007","volume":"46","author":[{"given":"R.","family":"Pirchio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. S.","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. E.","family":"Montini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Vergura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4049-2559","authenticated-orcid":false,"given":"A.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"issue":"1","key":"1980_CR1","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","volume":"5","author":"A Colao","year":"2019","unstructured":"Colao A, Grasso LFS, Giustina A, Melmed S, Chanson P, Pereira AM, Pivonello R (2019) Acromegaly. Nat Rev Dis Primers 5(1):20. https:\/\/doi.org\/10.1038\/s41572-019-0071-6. (Erratum in: Nat Rev Dis Primers. 2019 Oct 21; 5(1):72. PMID: 30899019)","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"1980_CR2","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1210\/er.2010-0002","volume":"32","author":"A Colao","year":"2011","unstructured":"Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32(2):247\u2013271. https:\/\/doi.org\/10.1210\/er.2010-0002","journal-title":"Endocr Rev"},{"issue":"11","key":"1980_CR3","doi-asserted-by":"publisher","first-page":"3933","DOI":"10.1210\/jc.2014-2700","volume":"99","author":"L Katznelson","year":"2014","unstructured":"Katznelson L, Laws ER Jr, Melmed S, Molitch ME, Murad MH, Utz A, Wass JA, Endocrine Society (2014) Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(11):3933\u20133951. https:\/\/doi.org\/10.1210\/jc.2014-2700","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"1980_CR4","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","volume":"342","author":"PJ Trainer","year":"2000","unstructured":"Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 342(16):1171\u20131177. https:\/\/doi.org\/10.1056\/NEJM200004203421604","journal-title":"N Engl J Med"},{"issue":"4","key":"1980_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","volume":"71","author":"PJ Trainer","year":"2009","unstructured":"Trainer PJ, Ezzat S, D\u2019Souza GA, Layton G, Strasburger CJ (2009) A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf) 71(4):549\u2013557. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03620.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1980_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s12020-018-1729-7","volume":"63","author":"LP Leonart","year":"2019","unstructured":"Leonart LP, Tonin FS, Ferreira VL, Fernandez-Llimos F, Pontarolo R (2019) Effectiveness and safety of pegvisomant: a systematic review and meta-analysis of observational longitudinal studies. Endocrine 63(1):18\u201326. https:\/\/doi.org\/10.1007\/s12020-018-1729-7","journal-title":"Endocrine"},{"issue":"9471","key":"1980_CR7","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1016\/S0140-6736(05)63011-5","volume":"365","author":"J Feenstra","year":"2005","unstructured":"Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ (2005) Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 365(9471):1644\u20131646. https:\/\/doi.org\/10.1016\/S0140-6736(05)63011-5. (Erratum in: Lancet. 2005 May; 365(9471):1620)","journal-title":"Lancet"},{"issue":"3","key":"1980_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1530\/eje.1.02112","volume":"154","author":"A Colao","year":"2006","unstructured":"Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154(3):467\u2013477. https:\/\/doi.org\/10.1530\/eje.1.02112","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1980_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/EJE-10-0867","volume":"164","author":"AJ van der Lely","year":"2011","unstructured":"van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, Neggers S, Birman P (2011) Coadministration of lanreotide autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 164(3):325\u2013333. https:\/\/doi.org\/10.1530\/EJE-10-0867","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"1980_CR10","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.1210\/jc.2007-1234","volume":"92","author":"SJ Neggers","year":"2007","unstructured":"Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 92(12):4598\u20134601. https:\/\/doi.org\/10.1210\/jc.2007-1234","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1980_CR11","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4158\/EP14330.OR","volume":"21","author":"PU Freda","year":"2015","unstructured":"Freda PU, Gordon MB, Kelepouris N, Jonsson P, Koltowska-Haggstrom M, van der Lely AJ (2015) Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY. Endocr Pract 21(3):264\u2013274. https:\/\/doi.org\/10.4158\/EP14330.OR","journal-title":"Endocr Pract"},{"issue":"4","key":"1980_CR12","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cen.12993","volume":"84","author":"AM Ramos-Lev\u00ed","year":"2016","unstructured":"Ramos-Lev\u00ed AM, Bernabeu I, \u00c1lvarez-Escol\u00e1 C, Aller J, Lucas T, de Miguel P, Rodr\u00edguez-Ca\u00f1ete L, Sampedro-N\u00fa\u00f1ez MA, Halperin I, Puig-Domingo M, Marazuela M (2016) Long-term treatment with pegvisomant for acromegaly: a 10-year experience. Clin Endocrinol (Oxf) 84(4):540\u2013550. https:\/\/doi.org\/10.1111\/cen.12993","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"1980_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1007\/s12020-016-0995-5","volume":"55","author":"RS Auriemma","year":"2017","unstructured":"Auriemma RS, Grasso LF, Galdiero M, Galderisi M, Pivonello C, Simeoli C, De Martino MC, Ferrigno R, Negri M, de Angelis C, Pivonello R, Colao A (2017) Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. Endocrine 55(3):872\u2013884. https:\/\/doi.org\/10.1007\/s12020-016-0995-5","journal-title":"Endocrine"},{"issue":"4","key":"1980_CR14","doi-asserted-by":"publisher","first-page":"320","DOI":"10.20945\/2359-3997000000160","volume":"63","author":"NXG Basavilbaso","year":"2019","unstructured":"Basavilbaso NXG, Ballarino MC, Bruera D, Bruno OD, Chervin AB, Danilowicz K, Fainstein-Day P, Fidalgo SG, Frigeri A, Glerean M, Guelman R, Isaac G, Katz DA, Knoblovits P, Librandi F, Montes ML, Mallea-Gil MS, Manavela M, Mereshian P, Moncet D, Pignatta A, Rogozinsky A, Sago LR, Servidio M, Spezzi M, Stalldecker G, Tkatch J, Vitale NM, Guitelman M (2019) Pegvisomant in acromegaly: a multicenter real-life study in Argentina. Arch Endocrinol Metab 63(4):320\u2013327. https:\/\/doi.org\/10.20945\/2359-3997000000160","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"1980_CR15","doi-asserted-by":"publisher","first-page":"328","DOI":"10.20945\/2359-3997000000159","volume":"63","author":"CL Boguszewski","year":"2019","unstructured":"Boguszewski CL, Huayllas MKP, Vilar L, Naves LA, Ribeiro-Oliveira Junior A, Soares BS, Czepielewski MA, Abucham J, Correa-Silva SR, Bronstein MD, Jallad RS, Duarte FG, Musolino NR, Kasuki L, Gadelha MR (2019) Brazilian multicenter study on pegvisomant treatment in acromegaly. Arch Endocrinol Metab. 63(4):328\u2013336. https:\/\/doi.org\/10.20945\/2359-3997000000159","journal-title":"Arch Endocrinol Metab."},{"issue":"2","key":"1980_CR16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1507\/endocrj.EJ19-0266","volume":"67","author":"H Yamaguchi","year":"2020","unstructured":"Yamaguchi H, Shimatsu A, Okayama A, Sato T (2020) Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance. Endocr J 67(2):201\u2013210. https:\/\/doi.org\/10.1507\/endocrj.EJ19-0266","journal-title":"Endocr J"},{"issue":"4","key":"1980_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1530\/EJE-21-0239","volume":"185","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, F\u00fchrer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J, Hey-Hadavi J, Camacho-Hubner C, Wajnrajch MP, Valluri SR, Palladino AA, Gomez R, Salvatori R (2021) More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol 185(4):525\u2013538. https:\/\/doi.org\/10.1530\/EJE-21-0239","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1980_CR18","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1210\/er.2002-0022","volume":"25","author":"A Colao","year":"2004","unstructured":"Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25(1):102\u2013152. https:\/\/doi.org\/10.1210\/er.2002-0022","journal-title":"Endocr Rev"},{"issue":"1","key":"1980_CR19","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11102-017-0797-7","volume":"20","author":"R Pivonello","year":"2017","unstructured":"Pivonello R, Auriemma RS, Grasso LF, Pivonello C, Simeoli C, Patalano R, Galdiero M, Colao A (2017) Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 20(1):46\u201362. https:\/\/doi.org\/10.1007\/s11102-017-0797-7","journal-title":"Pituitary"},{"issue":"7","key":"1980_CR20","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2018-02281","volume":"104","author":"T Feola","year":"2019","unstructured":"Feola T, Cozzolino A, Simonelli I, Sbardella E, Pozza C, Giannetta E, Gianfrilli D, Pasqualetti P, Lenzi A, Isidori AM (2019) Pegvisomant improves glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab 104(7):2892\u20132902. https:\/\/doi.org\/10.1210\/jc.2018-02281","journal-title":"J Clin Endocrinol Metab"},{"key":"1980_CR21","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2017-02566","author":"A Cozzolino","year":"2018","unstructured":"Cozzolino A, Feola T, Simonelli I, Puliani G, Pozza C, Giannetta E, Gianfrilli D, Pasqualetti P, Lenzi A, Isidori AM (2018) Somatostatin analogs and glucose metabolism in acromegaly: a meta-analysis of prospective interventional studies. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2017-02566","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1980_CR22","doi-asserted-by":"publisher","first-page":"dgz096","DOI":"10.1210\/clinem\/dgz096","volume":"105","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein MD, Casanueva FF, Clemmons D, Colao A, Ferone D, Fleseriu M, Frara S, Gadelha MR, Ghigo E, Gurnell M, Heaney AP, Ho K, Ioachimescu A, Katznelson L, Kelestimur F, Kopchick J, Krsek M, Lamberts S, Losa M, Luger A, Maffei P, Marazuela M, Mazziotti G, Mercado M, Mortini P, Neggers S, Pereira AM, Petersenn S, Puig-Domingo M, Salvatori R, Shimon I, Strasburger C, Tsagarakis S, van der Lely AJ, Wass J, Zatelli MC, Melmed SA (2020) Consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab 105(4):dgz096. https:\/\/doi.org\/10.1210\/clinem\/dgz096","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1980_CR23","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1210\/jcem.85.2.6363","volume":"85","author":"A Giustina","year":"2000","unstructured":"Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85(2):526\u2013529. https:\/\/doi.org\/10.1210\/jcem.85.2.6363","journal-title":"J Clin Endocrinol Metab"},{"key":"1980_CR24","volume-title":"Obesity: preventing and managing the global epidemic","author":"World Health Organization","year":"2000","unstructured":"World Health Organization (2000) Obesity: preventing and managing the global epidemic. World Health Organization, Geneva"},{"issue":"6","key":"1980_CR25","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","volume":"42","author":"AV Chobanian","year":"2003","unstructured":"Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee (2003) Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 42(6):1206\u20131252. https:\/\/doi.org\/10.1161\/01.HYP.0000107251.49515.c2","journal-title":"Hypertension"},{"key":"1980_CR26","volume-title":"Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation part 1\u2014diagnosis and classification of diabetes mellitus","author":"World Health Organization","year":"1999","unstructured":"World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation part 1\u2014diagnosis and classification of diabetes mellitus. World Health Organization, Geneva"},{"key":"1980_CR27","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","volume":"285","author":"Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults","year":"2001","unstructured":"Expert Panel on Detection Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) Expert panel on detection evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486\u20132497","journal-title":"JAMA"},{"issue":"7","key":"1980_CR28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/BF00280883","volume":"28","author":"DR Matthews","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28(7):412\u2013419. https:\/\/doi.org\/10.1007\/BF00280883","journal-title":"Diabetologia"},{"issue":"3","key":"1980_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/s0168-8227(99)00116-3","volume":"47","author":"M Gutt","year":"2000","unstructured":"Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, Czarnecki EM, Schneiderman N, Skyler JS, Marks JB (2000) Validation of the insulin sensitivity index (ISI(0,120)): comparison with other measures. Diabetes Res Clin Pract 47(3):177\u2013184. https:\/\/doi.org\/10.1016\/s0168-8227(99)00116-3","journal-title":"Diabetes Res Clin Pract"},{"issue":"10","key":"1980_CR30","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1210\/jc.2009-0941","volume":"94","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Galdiero M, Lombardi G, Pivonello R (2009) Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab 94(10):3746\u20133756. https:\/\/doi.org\/10.1210\/jc.2009-0941","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1980_CR31","doi-asserted-by":"publisher","first-page":"3132","DOI":"10.1210\/jcem.85.9.6782","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao A, Marzullo P, Ferone D, Spinelli L, Cuocolo A, Bonaduce D, Salvatore M, Boerlin V, Lancranjan I, Lombardi G (2000) Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly. J Clin Endocrinol Metab 85(9):3132\u20133140. https:\/\/doi.org\/10.1210\/jcem.85.9.6782","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1980_CR32","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1210\/jcem.86.6.7556","volume":"86","author":"A Colao","year":"2001","unstructured":"Colao A, Ferone D, Marzullo P, Cappabianca P, Cirillo S, Boerlin V, Lancranjan I, Lombardi G (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 86(6):2779\u20132786. https:\/\/doi.org\/10.1210\/jcem.86.6.7556","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1980_CR33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1365-2265.2008.03208.x","volume":"69","author":"P Chanson","year":"2008","unstructured":"Chanson P, Borson-Chazot F, Kuhn JM, Blumberg J, Maisonobe P, Delemer B, Lanreotide Acromegaly Study Group (2008) Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) 69(2):299\u2013305. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03208.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1980_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1365-2265.2008.03503.x","volume":"71","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Rebora A, Galdiero M, Resmini E, Minuto F, Lombardi G, Pivonello R, Ferone D (2009) Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) 71(2):237\u2013245. https:\/\/doi.org\/10.1111\/j.1365-2265.2008.03503.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1980_CR35","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1530\/EJE-07-0383","volume":"157","author":"A Colao","year":"2007","unstructured":"Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2007) Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157(5):579\u2013587. https:\/\/doi.org\/10.1530\/EJE-07-0383","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"1980_CR36","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1365-2265.2007.02878.x","volume":"67","author":"JC Maiza","year":"2007","unstructured":"Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, Bennet A, Caron P (2007) Long-term (up to 18 years) effects on GH\/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 67(2):282\u2013289. https:\/\/doi.org\/10.1111\/j.1365-2265.2007.02878.x","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1980_CR37","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Pr\u00e9vost G, Maisonobe P, Clermont A, Investigators PRIMARYS (2014) Tumor shrinkage with lanreotide Autogel 120 mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 99(4):1282\u20131290. https:\/\/doi.org\/10.1210\/jc.2013-3318","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1980_CR38","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11102-011-0365-5","volume":"15","author":"C Giordano","year":"2012","unstructured":"Giordano C, Ciresi A, Amato MC, Pivonello R, Auriemma RS, Grasso LF, Galluzzo A, Colao A (2012) Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 15(4):539\u2013551. https:\/\/doi.org\/10.1007\/s11102-011-0365-5","journal-title":"Pituitary"},{"issue":"8","key":"1980_CR39","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1210\/jc.2008-2627","volume":"94","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Savastano S, Galdiero M, Grasso LF, Lombardi G, Pivonello R (2009) Glucose tolerance and somatostatin analog treatment in acromegaly: a 12-month study. J Clin Endocrinol Metab 94(8):2907\u20132914. https:\/\/doi.org\/10.1210\/jc.2008-2627","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1980_CR40","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1210\/jc.2008-1546","volume":"94","author":"A Colao","year":"2009","unstructured":"Colao A, Auriemma RS, Galdiero M, Cappabianca P, Cavallo LM, Esposito F, Grasso LF, Lombardi G, Pivonello R (2009) Impact of somatostatin analogs versus surgery on glucose metabolism in acromegaly: results of a 5-year observational, open, prospective study. J Clin Endocrinol Metab 94(2):528\u2013537. https:\/\/doi.org\/10.1210\/jc.2008-1546","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1980_CR41","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1210\/jc.2012-3072","volume":"98","author":"AK Annamalai","year":"2013","unstructured":"Annamalai AK, Webb A, Kandasamy N, Elkhawad M, Moir S, Khan F, Maki-Petaja K, Gayton EL, Strey CH, O\u2019Toole S, Ariyaratnam S, Halsall DJ, Chaudhry AN, Berman L, Scoffings DJ, Antoun NM, Dutka DP, Wilkinson IB, Shneerson JM, Pickard JD, Simpson HL, Gurnell M (2013) A comprehensive study of clinical, biochemical, radiological, vascular, cardiac, and sleep parameters in an unselected cohort of patients with acromegaly undergoing presurgical somatostatin receptor ligand therapy. J Clin Endocrinol Metab 98(3):1040\u20131050. https:\/\/doi.org\/10.1210\/jc.2012-3072","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1980_CR42","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1210\/jc.2008-0299","volume":"93","author":"A Colao","year":"2008","unstructured":"Colao A, Pivonello R, Galderisi M, Cappabianca P, Auriemma RS, Galdiero M, Cavallo LM, Esposito F, Lombardi G (2008) Impact of treating acromegaly first with surgery or somatostatin analogs on cardiomyopathy. J Clin Endocrinol Metab 93(7):2639\u20132646. https:\/\/doi.org\/10.1210\/jc.2008-0299","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1980_CR43","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","volume":"87","author":"G Sesmilo","year":"2002","unstructured":"Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab 87(4):1692\u20131699. https:\/\/doi.org\/10.1210\/jcem.87.4.8364","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1980_CR44","doi-asserted-by":"publisher","first-page":"bvab004","DOI":"10.1210\/jendso\/bvab004","volume":"5","author":"AP Kuker","year":"2021","unstructured":"Kuker AP, Shen W, Jin Z, Singh S, Chen J, Bruce JN, Freda PU (2021) Body composition changes with long-term pegvisomant therapy of acromegaly. J Endocr Soc. 5(3):bvab004. https:\/\/doi.org\/10.1210\/jendso\/bvab004","journal-title":"J Endocr Soc."}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01980-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01980-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01980-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,15]],"date-time":"2023-04-15T16:10:53Z","timestamp":1681575053000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01980-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["1980"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01980-7","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"21 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RP, RSA, MEM, AV declare they have no financial interests. AC has been Principal Investigator of Research Studies for Novartis, Ipsen, Pfizer, Lilly, Merck and Novo Nordisk; consultant for Novartis, Ipsen, Pfizer, and received honoraria from Novartis, Ipsen and Pfizer beyond the confines of this work. RPiv has been Principal Investigator of Clinical and\/or Translational Research Studies for Novartis, HRA Pharma, Ipsen, Shire, Corcept Therapeutics, Cortendo AB, Janssen Cilag, Camurus, Strongbridge, and Pfizer; Co-investigator of Research Studies for Pfizer; received research grants from Novartis, Pfizer, Ipsen, HRA Pharma, Shire, IBSA, Strongbridge Biopharma; has been an occasional consultant for Novartis, Ipsen, Pfizer, Shire, HRA Pharma, Cortendo AB, Ferring, Strongbridge Biopharma, Recordati, Corcept Therapeutics, Crinetics Pharmaceuticals, ARH Healthcare, Biohealth Italia; and has received fees and honoraria for presentations from Novartis, Shire, Pfizer and Recordati beyond the confines of this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval was obtained from the ethics committee of \u201cFedericoII\u201d University (amendment 27\/06\/2002). The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}